Citation: | ZHENG Guoxue, KANG Tengyao, ZHONG Wei, CHEN Kai, LI Gangzhi. Research progress on relationships of ABO blood types with venous thromboembolism[J]. Journal of Clinical Medicine in Practice, 2022, 26(9): 144-148. DOI: 10.7619/jcmp.20214383 |
[1] |
DI NISIO M, VAN ES N, BVLLER H R. Deep vein thrombosis and pulmonary embolism[J]. Lancet, 2016, 388(10063): 3060-3073. doi: 10.1016/S0140-6736(16)30514-1
|
[2] |
尹建华, 朱见伟, 顾立超, 等. 早期诊断对老年肺栓塞患者的临床价值[J]. 实用临床医药杂志, 2019, 23(17): 103-106. doi: 10.7619/jcmp.201917029
|
[3] |
MÉAN M, LIMACHER A, ALATRI A, et al. Derivation and validation of a prediction model for risk stratification of post-thrombotic syndrome in elderly patients with a first deep vein thrombosis[J]. Thromb Haemost, 2018, 118(8): 1419-1427. doi: 10.1055/s-0038-1661392
|
[4] |
KHALIL A, FEGHALI R, HASSOUN M. The Lebanese COVID-19 cohort; A challenge for the ABO blood group system[J]. Front Med (Lausanne), 2020, 7: 585341.
|
[5] |
LI Y X, LIU L Y, HUANG Y B, et al. Association of ABO polymorphisms and pancreatic cancer/cardiocerebrovascular disease: a meta-analysis[J]. BMC Med Genet, 2020, 21(1): 41. doi: 10.1186/s12881-020-0975-8
|
[6] |
STOWELL S R, STOWELL C P. Biologic roles of the ABH and Lewis histo-blood group antigens part Ⅱ: thrombosis, cardiovascular disease and metabolism[J]. Vox Sang, 2019, 114(6): 535-552. doi: 10.1111/vox.12786
|
[7] |
SCHEINER B, NORTHUP P G, GRUBER A B, et al. The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease[J]. Liver Int, 2020, 40(6): 1415-1426. doi: 10.1111/liv.14404
|
[8] |
李观强, 吴凡, 韦利, 等. ABO血型与深静脉血栓发生风险关系的病例对照研究及Meta分析[J]. 中国普通外科杂志, 2020, 29(6): 677-685. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202006010.htm
|
[9] |
VASAN S K, ROSTGAARD K, MAJEED A, et al. ABO blood group and risk of thromboembolic and arterial disease: a study of 1. 5 million blood donors[J]. Circulation, 2016, 133(15): 1449-1457. doi: 10.1161/CIRCULATIONAHA.115.017563
|
[10] |
张国桃, 乔雪丽, 张明星. 血型对育龄期临产孕妇凝血功能的影响[J]. 实用临床医药杂志, 2018, 22(9): 121-123. doi: 10.7619/jcmp.201809035
|
[11] |
HADDAD R A, ALNIMER Y, ABDALLA A, et al. Is peripherally inserted central catheter-related thrombosis associated with ABO blood group A case-control pilot study[J]. Clin Appl Thromb Hemost, 2018, 24(8): 1297-1300. doi: 10.1177/1076029618770289
|
[12] |
CARTER Y M, CAPS M T, MEISSNER M H. Deep venous thrombosis and ABO blood group are unrelated in trauma patients[J]. J Trauma, 2002, 52(1): 112-116.
|
[13] |
施志能. 多发伤患者ABO血型与深静脉血栓形成的关系研究[D]. 上海: 上海交通大学, 2016.
|
[14] |
DUBINSKI D, KEIL F, WON S Y, et al. Pulmonary embolism in neurocritical care-introduction of a novel grading system for risk stratification: the Frankfurt AMBOS score[J]. Neurosurg Rev, 2021, 44(2): 1165-1171. doi: 10.1007/s10143-020-01310-6
|
[15] |
赵海歌. ABO血型、vWF和凝血因子Ⅷ与肺血栓栓塞相关性的研究[D]. 保定: 河北大学, 2017.
|
[16] |
HAJIZADEH R, KAVANDI H, NADIRI M, et al. Association of ABO blood group with incidence and outcome of acute pulmonary embolism[J]. Turk Kardiyol Dern Ars, 2016, 44(5): 397-403.
|
[17] |
KAHN S R. The post-thrombotic syndrome[J]. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 413-418. doi: 10.1182/asheducation-2016.1.413
|
[18] |
NAWASRAH J, ZYDEK B, LUCKS J, et al. Incidence and severity of postthrombotic syndrome after iliofemoral thrombosis - results of the Iliaca-PTS - Registry[J]. Vasa, 2021, 50(1): 30-37. doi: 10.1024/0301-1526/a000933
|
[19] |
GALANAUD J P, RIGHINI M, LE COLLEN L, et al. Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: the CACTUS-PTS study[J]. J Thromb Haemost, 2020, 18(4): 857-864. doi: 10.1111/jth.14728
|
[20] |
汪涛, 范隆华, 刘坚军, 等. 下肢深静脉血栓后综合征高危因素的logistic回归分析[J]. 中华血管外科杂志, 2019, 4(2): 97-101. doi: 10.3760/cma.j.issn.2096-1863.2019.02.007
|
[21] |
MUSTO L, MOORE H, SAHA P. Challenges in revascularization of the venous circulation: deep vein thrombosis, venous disorders, and the role of deep venous stenting[J]. Debulking in Cardiovascular Interventions and Revascularization Strategies, 2022: 765-774.
|
[22] |
SPIEZIA L, CAMPELLO E, VALLE F D, et al. ABO blood group and the risk of post-thrombotic syndrome[J]. Ann Hematol, 2018, 97(6): 1057-1060. doi: 10.1007/s00277-018-3255-3
|
[23] |
GALANAUD J P, HOLCROFT C A, RODGER M A, et al. Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency[J]. J Thromb Haemost, 2013, 11(3): 474-480. doi: 10.1111/jth.12106
|
[24] |
朱杰, 樊静雯, 许小毛. 残余血栓对静脉血栓栓塞症预后的影响研究进展[J]. 中华结核和呼吸杂志, 2019, 42(2): 114-118. doi: 10.3760/cma.j.issn.1001-0939.2019.02.007
|
[25] |
李雪. 再发性肺栓塞的危险因素分析[D]. 青岛: 青岛大学, 2017.
|
[26] |
冯骄. AngioJet机械性血栓清除与导管接触溶栓治疗急性下肢深静脉血栓形成的对比研究[D]. 成都: 成都医学院, 2020.
|
[27] |
DENTALI F, DI MINNO M N D, TURATO S, et al. Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis[J]. Thromb Res, 2014, 134(2): 264-267. doi: 10.1016/j.thromres.2014.05.016
|
[28] |
KHAN F, RAHMAN A, CARRIER M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis[J]. BMJ, 2019, 366: l4363.
|
[29] |
DE MEYER S F, DECKMYN H, VANHOORELBEKE K. Von Willebrand factor to the rescue[J]. Blood, 2009, 113(21): 5049-5057. doi: 10.1182/blood-2008-10-165621
|
[30] |
袁忠海, 赵军, 张英, 等. vWF基因A1381T多态性和ABO血型对血浆vWF水平的影响[J]. 中国实验血液学杂志, 2010, 18(4): 967-971. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201004035.htm
|
[31] |
TSAI A W, CUSHMAN M, ROSAMOND W D, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE)[J]. Am J Med, 2002, 113(8): 636-642. doi: 10.1016/S0002-9343(02)01345-1
|
[32] |
LINDSTRÖM S, BRODY J A, TURMAN C, et al. A large-scale exome array analysis of venous thromboembolism[J]. Genet Epidemiol, 2019, 43(4): 449-457. doi: 10.1002/gepi.22187
|
[33] |
BRUZELIUS M, STRAWBRIDGE R J, TRÉGOUËT D A, et al. Influence of coronary artery disease-associated genetic variants on risk of venous thromboembolism[J]. Thromb Res, 2014, 134(2): 426-432. doi: 10.1016/j.thromres.2014.03.054
|
[34] |
HEIT J A, CUNNINGHAM J M, PETTERSON T M, et al. Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism[J]. J Thromb Haemost, 2011, 9(6): 1133-1142. doi: 10.1111/j.1538-7836.2011.04272.x
|
[35] |
MANCO L, SILVA C, FIDALGO T, et al. Venous thromboembolism risk associated with ABO, F11 and FGG loci[J]. Blood Coagul Fibrinolysis, 2018, 29(6): 528-532. doi: 10.1097/MBC.0000000000000753
|
[36] |
HEIT J A, ARMASU S M, ASMANN Y W, et al. A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24. 2 and 9q[J]. J Thromb Haemost, 2012, 10(8): 1521-1531. doi: 10.1111/j.1538-7836.2012.04810.x
|
[37] |
WU O, BAYOUMI N, VICKERS M A, et al. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis[J]. J Thromb Haemost, 2008, 6(1): 62-69.
|
[38] |
ALBÁNEZ S, OGIWARA K, MICHELS A, et al. Aging and ABO blood type influence von Willebrand factor and factor VⅢ levels through interrelated mechanisms[J]. J Thromb Haemost, 2016, 14(5): 953-963. doi: 10.1111/jth.13294
|
[39] |
MORANGE P E, TREGOUET D A. Lessons from genome-wide association studies in venous thrombosis[J]. J Thromb Haemost, 2011, 9(Suppl 1): 258-264.
|
[40] |
IBRAHIM-KOSTA M, BAILLY P, SILVY M, et al. ABO blood group, glycosyltransferase activity and risk of venous thromboembolism[J]. Thromb Res, 2020, 193: 31-35. doi: 10.1016/j.thromres.2020.05.051
|
[41] |
JIA Q, HAN Y, HUANG P, et al. Genetic determinants of circulating Glycine levels and risk of coronary artery disease[J]. J Am Heart Assoc, 2019, 8(10): e011922. doi: 10.1161/JAHA.119.011922
|
[42] |
ZHANG W J, XU Q, ZHUANG Y L, et al. Novel association of soluble intercellular adhesion molecule 1 and soluble P-selectin with the ABO blood group in a Chinese population[J]. Exp Ther Med, 2016, 12(2): 909-914. doi: 10.3892/etm.2016.3347
|
[43] |
FENG Q Q, WANG M Y, MUHTAR E, et al. Nanoparticles of a new small-molecule P-selectin inhibitor attenuate thrombosis, inflammation, and tumor growth in two animal models[J]. Int J Nanomedicine, 2021, 16: 5777-5795. doi: 10.2147/IJN.S316863
|